In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Expect change in Germany: Pharma Dialogue gives industry hope

This article was originally published in Scrip

Executive Summary

Germany's government has set up a series of workshops, called the "Pharma Dialogue", which give the native pharma industry a platform for the next year from which to share its victories and air its grievances. Many are hoping to see legislative changes as a result of the dialogue sessions that favor industry more than Germany's most recent tweaks.

You may also be interested in...



WuXi eases CAR-T manufacturing burden with new US plant

China's WuXi PharmaTech, an R&D technology company serving the pharmaceutical, biotechnology and medical device industries, has announced construction of a new manufacturing facility in Philadelphia, US designed for cell therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. More manufacturing power is crucial to the success of this burgeoning, high-potential field.

NICE lifts Entyvio restrictions after Takeda offers discount

Takeda has managed to persuade NICE, the health technology appraisal institute for England and Wales, to recommend its ulcerative colitis drug Entyvio (vedolizumab) without the restrictions the institute had previously stipulated – as long as the company offers a discount via a patient access scheme.

10 things you need to know about Canada's best-kept market access secret

Some of you will be familiar with it, many of you may not even have heard of it, but the pharmaceutical industry needs to know about it; we're talking about Canada's pan-Canadian Pharmaceutical Alliance (pCPA). Currently run with no formal office or resources, by people who have taken it on as extra work on top of their usual day job, the pCPA has still managed to become a formidable market access force in Canada since its inception in 2010. Its decisions are make or break for pharmaceutical companies targeting the market, and changes on the horizon mean its importance is set to increase.

Topics

UsernamePublicRestriction

Register

ID1125347

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel